TUCSON, Ariz., Nov. 27, 2017 — Accelerate Diagnostics, Inc. has teamed up with Sepsis Alliance for #GivingTuesday, November 28th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide.Accelerate Diagnostics has pledged to match the first $10,000 gifted to Sepsis Alliance on #GivingTuesday to help raise awareness of sepsis as an often preventable medical emergency.Sepsis is the body's life-threatening response to infection that can affect anyone and lead to death. According to the Sepsis Alliance, the leading U.S. organization dedicated to this cause, as many as forty percent of patients diagnosed with septic shock do not survive. Early recognition and appropriate antibiotics are keys to treating sepsis. “We’re glad to support this important worldwide effort to raise awareness of this life-threatening emergency that is so often misunderstood,” said Larry Mehren, President & CEO of Accelerate Diagnostics. “The commitment from the team at Sepsis Alliance to create meaningful improvements for patients is evident and aligns well with our own to make life-saving decisions easier for clinicians and safer for patients afflicted with serious infections.”To donate to the Sepsis Alliance campaign, please visit: https://donate.sepsis.org/checkout/donation?eid=155997About Sepsis AllianceSepsis Alliance is the nation’s leading sepsis advocacy organization, dedicated to saving lives by raising awareness of sepsis as a medical emergency. A 501(c)(3) organization, Sepsis Alliance was founded by Dr. Carl Flatley after the sudden, unnecessary death of his daughter Erin to a disease he had never even heard of. Sepsis Alliance produces and distributes educational materials for patients, families and health providers on sepsis prevention, early recognition and treatment. The organization also offers support to patients, sepsis survivors, and family members through its sepsis.org website which receives more than 1.5 million visits each year. The organization founded Sepsis Awareness Month in 2011, and works with partners to host community outreach events across North America. Since Sepsis Alliance began its mission, sepsis awareness has increased threefold, from 19% to 58%. For more information on Sepsis Alliance, a GuideStar Gold-rated charity, please visit http://www.sepsis.org/.About #GivingTuesday#GivingTuesday is a global giving movement that has been built by individuals, families, organizations, businesses and communities in all 50 states and in countries around the world. This year, #GivingTuesday falls on November 28. #GivingTuesday harnesses the collective power of a unique blend of partners to transform how people think about, talk about, and participate in the giving season. It inspires people to take collective action to improve their communities, give back in better, smarter ways to the charities and causes they believe in, and help create a better world. Every act of generosity counts, and they mean even more when we give together. To learn more about #GivingTuesday, please visit: www.givingtuesday.org.About Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc. (“Accelerate”) (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. Recent market studies suggest the solution offers results 1-2 days faster than conventional methods, enabling clinicians to optimize antibiotic selection, dosage, and infusion strategy specific to the individual patient and their infection. To learn more, visit axdx.com.Media Contact:Andrew Chasteen+1 520 365-3100